Schonfeld Strategic Advisors’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $18.9M | Buy |
+324,722
| New | +$15M | 0.15% | 169 |
|
|
2025
Q4 | – | Sell |
-12,652
| Closed | -$508K | – | 2670 |
|
|
2025
Q3 | $508K | Buy |
12,652
+2,114
| +20% | +$74.5K | ﹤0.01% | 1679 |
|
|
2025
Q2 | $330K | Sell |
10,538
-12,416
| -54% | -$405K | ﹤0.01% | 1664 |
|
|
2025
Q1 | $770K | Buy |
22,954
+7,804
| +52% | +$296K | 0.01% | 1392 |
|
|
2024
Q4 | $594K | Buy |
15,150
+1,568
| +12% | +$64.8K | ﹤0.01% | 1323 |
|
|
2024
Q3 | $535K | Sell |
13,582
-18,678
| -58% | -$753K | ﹤0.01% | 1402 |
|
|
2024
Q2 | $1.26M | Sell |
32,260
-47,691
| -60% | -$1.91M | 0.01% | 1104 |
|
|
2024
Q1 | $3.44M | Sell |
79,951
-7,549
| -9% | -$347K | 0.03% | 779 |
|
|
2023
Q4 | $4.03M | Sell |
87,500
-111,484
| -56% | -$3.94M | 0.03% | 571 |
|
|
2023
Q3 | $6.8M | Buy |
198,984
+18,841
| +10% | +$705K | 0.06% | 461 |
|
|
2023
Q2 | $6.94M | Sell |
180,143
-119,976
| -40% | -$4.77M | 0.06% | 426 |
|
|
2023
Q1 | $10.7M | Buy |
300,119
+131,706
| +78% | +$4.87M | 0.1% | 267 |
|
|
2022
Q4 | $6.64M | Buy |
168,413
+60,129
| +56% | +$2.19M | 0.06% | 403 |
|
|
2022
Q3 | $3.91M | Sell |
108,284
-19,825
| -15% | -$713K | 0.03% | 613 |
|
|
2022
Q2 | $3.9M | Buy |
128,109
+25,735
| +25% | +$778K | 0.04% | 539 |
|
|
2022
Q1 | $3.13M | Buy |
102,374
+13,474
| +15% | +$403K | 0.03% | 582 |
|
|
2021
Q4 | $2.78M | Sell |
88,900
-31,221
| -26% | -$933K | 0.03% | 614 |
|
|
2021
Q3 | $1.84M | Buy |
120,121
+23,521
| +24% | +$409K | 0.02% | 744 |
|
|
2021
Q2 | $1.8M | Buy |
96,600
+13,200
| +16% | +$243K | 0.02% | 754 |
|
|
2021
Q1 | $1.49M | Buy |
83,400
+10,800
| +15% | +$183K | 0.02% | 753 |
|
|
2020
Q4 | $1.12M | Buy |
72,600
+10,000
| +16% | +$117K | 0.02% | 770 |
|
|
2020
Q3 | $693K | Buy |
62,600
+27,000
| +76% | +$318K | 0.01% | 812 |
|
|
2020
Q2 | $447K | Buy |
35,600
+22,600
| +174% | +$288K | 0.01% | 844 |
|
|
2020
Q1 | $147K | Sell |
13,000
-56,400
| -81% | -$803K | 0.01% | 963 |
|
|
2019
Q4 | $910K | Buy |
+69,400
| New | +$730K | 0.02% | 541 |
|
|
2019
Q2 | – | Sell |
-500,000
| Closed | -$5.08M | – | 1285 |
|
|
2019
Q1 | $5.08M | Buy |
500,000
+9,942
| +2% | +$84.3K | 0.18% | 156 |
|
|
2018
Q4 | $3.09M | Sell |
490,058
-72,355
| -13% | -$643K | 0.12% | 235 |
|
|
2018
Q3 | $7.42M | Buy |
562,413
+107,413
| +24% | +$1.24M | 0.33% | 74 |
|
|
2018
Q2 | $4.19M | Buy |
455,000
+70,000
| +18% | +$435K | 0.23% | 153 |
|
|
2018
Q1 | $1.89M | Hold |
385,000
| – | – | 0.14% | 209 |
|
|
2017
Q4 | $1.09M | Buy |
385,000
+110,000
| +40% | +$299K | 0.09% | 294 |
|
|
2017
Q3 | $811K | Buy |
275,000
+150,000
| +120% | +$464K | 0.07% | 296 |
|
|
2017
Q2 | $394K | Buy |
+125,000
| New | +$489K | 0.04% | 432 |
|
Other funds holding XENE
ACA
DCM
PCH
